Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentethylquine is a long-acting anticholinergic small molecule drug, independently developed by the Chinese Academy of Military Sciences. It is primarily known for its highly selective antagonistic effects on M1 and M3 muscarinic acetylcholine receptors, with a weaker antagonistic effect on M2 receptors. Additionally, it acts as an antagonist at N cholinergic receptors. These actions lead to the inhibition of glandular secretion and other anticholinergic effects. It is utilized in medical settings, including as an adjunct in anesthesia induction, and has shown potential therapeutic value in conditions such as organophosphorus poisoning and various respiratory diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentethylquine.